GSK plc
GSKHealthcareNASDAQDrug Manufacturers - General
Scan Results
Daily timeframeHeadquartered within the healthcare sector, GSK plc focuses on Drug Manufacturers - General services and products. GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United. The company carries a $103.66B market cap, placing it firmly in the large-cap category. It operates through Commercial Operations and Total R&D segments.
Market Cap
$103.66B
Beta
0.30
P/E (TTM)
14.07
P/E (Fwd)
10.03
EPS (TTM)
$3.68
EPS (Fwd)
$5.16
ROE
40.9%
ROA
10.0%
Cash
$3.44B
Total Debt
$19.11B
Free CF
$3.02B
52W Change
42.5%
Annual Financials
Cash vs Debt
The company holds $3.44B in cash, though total debt stands at $19.11B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Annual free cash flow of $3.02B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 40.9%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 10.0% further supports the picture of efficient asset utilization. Revenue has been uneven over recent years, ranging from $29.32B to $32.67B.
With a beta below 0.7, GSK plc typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence GSK plc's trajectory.